GSK to buy IDRx for up to $1.15bn

By Frank Prenesti

Date: Monday 13 Jan 2025

(Sharecast News) - GSK on Monday said it was buying US-based biopharmaceutical company IDRx for up to $1.15bn.

IDRx specialises in developing treatments for gastrointestinal stromal tumours (GIST), GSK will pay $1bn up front with the potential for a further milestone payment of $150m.

Reporting by Frank Prenesti for Sharecast.com

« Go back to news channel

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE